More is better but .... how is best: Are milligrams over hours better than grams over minutes? The case of gemcitabine

被引：10

作者：

Pollera, CF

机构：

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1997年 / 15卷 / 05期

关键词：

D O I：

10.1200/JCO.1997.15.5.2172

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2172 / 2173

页数：2

共 8 条

[1] A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer [J].

Anderson, H ;

Thatcher, N ;

Walling, J ;

Hansen, H .

BRITISH JOURNAL OF CANCER, 1996, 74 (03) :460-462

[2]

Dent SF, 1996, ANN ONCOL, V7, P561

[3] SATURATION OF 2',2'-DIFLUORODEOXYCYTIDINE 5'-TRIPHOSPHATE ACCUMULATION BY MONONUCLEAR-CELLS DURING A PHASE-I TRIAL OF GEMCITABINE [J].

GRUNEWALD, R ;

ABBRUZZESE, JL ;

TARASSOFF, P ;

PLUNKETT, W .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 27 (04) :258-262

[4] GEMCITABINE - CURRENT STATUS OF PHASE-I AND PHASE-II TRIALS [J].

KAYE, SB .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1527-1531

[5] WEEKLY GEMCITABINE IN ADVANCED OR METASTATIC SOLID TUMORS - A CLINICAL-PHASE-I STUDY [J].

POLLERA, CF ;

CERIBELLI, A ;

CRECCO, M ;

CALABRESI, F .

INVESTIGATIONAL NEW DRUGS, 1994, 12 (02) :111-119

[6]

POLLERA CF, 1996, P AM SOC CLIN ONCOL, V15, P486

[7] Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematic modeling to determine maximum-tolerable dose [J].

Shepherd, FA ;

Burkes, R ;

Cormier, Y ;

Crump, M ;

Feld, R ;

Strack, T ;

Schulz, M .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1656-1662

[8] Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors [J].

Veerman, G ;

vanHaperen, VWTR ;

Vermorken, JB ;

Noordhuis, P ;

Braakhuis, BJM ;

Pinedo, HM ;

Peters, GJ .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (04) :335-342

← 1 →